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medication (RR 1.5; 95%CI 1.4-1.7). Corresponding PAR%was 3%. CONCLUSIONS: In
the first year of life, preterm born infants are up to 2.0 times more likely than full
term borns to be hospitalized or use medication, especially related to respiratory
disease.
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OBJECTIVES: A dietary supplement (DS) is defined as “any product intended for
ingestion as a supplement to the diet.” These substances include vitamins, miner-
als, herbs, amino acids, and other substances. Marketing data show a dramatic
increase in DS sales in the last decade. Themost recent published literature on the
prevalence of DS use in United States was based on data from 1999-2000. There is
a need for updated literature. The objective of this study was to measure the prev-
alence of DS use and to examine associations of its use with select demographic
characteristics in the United States. METHODS: DS data from 2007–2009 National
Health and Nutrition Examination Survey (NHANES), a nationally representative,
cross-sectional survey of UShealth andnutrition,was analyzed. The proportions of
users of any DS, multivitamins/multiminerals, vitamin-B-complex, calcium, calci-
um/antacids were calculated. Bivariate and Multivariate analyses were done to
assess the relationship of DS use and some demographic/lifestyle characteristics.
RESULTS: Approximately 43% of US population reported taking DS(s) in the past
month; DSs were consumed by females (48%) more than males (38%), youngers
(0-11 years; 33%) and elders (40 years and more; 59%) more than middle age (12-39
years; 29%), more than high school educated people (56%) than less than high
school (30%), non-Hispanic Whites (50%) more than other races (average 30%).
Multivitamins/multiminerals were the most commonly consumed DS (60%) fol-
lowed by antacid, vitamin B-complex and vitamin C. In bivariate analyses non-
HispanicWhite race, older age categories,more education, and female genderwere
significantly associated with greater use of any DS. In multivariable analysis the
latter three characteristics were still associatedwith greater use.CONCLUSIONS:A
substantial proportion of the US population takes DSmainly as vitamins,minerals,
and/or other dietary supplements. This study provides detailed information for
health care professionals and researchers regarding the DS use.
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OBJECTIVES: Selective serotonin reuptake inhibitors (SSRIs) have been associated
with increased risk of osteoporotic-related fractures. Bisphosphonates (BPs) are
one of the recommended medications for osteoporosis and fracture prevention.
The primary objective of this study was to examine the proportion of BP users who
are also on SSRIs and to explore the relationship between concomitant use and
patient age among women aged 45 years and older. METHODS: Data from the
2004-2008 Medical Expenditure Panel Survey (MEPS) was used to examine usage
patterns of BPs and SSRIs for women aged 45 years. Analyses were based on
yearly consolidated data and prescribed medicines files. Weighed descriptive sta-
tistics were used to evaluate patterns of medications use and proportions were
reported. Age was categorized into two groups: 45-64, and 65-85 years old.
RESULTS: In the timeframe examined, 3.5% women in 2004, 3.8% in 2005, 4.0% in
2006, 3.9% in 2007, and 4.0% in 2008 received bisphosphonates. In the same period,
8.6% women in 2004, 8.5% in 2005, 8.1% in 2006, 7.4% in 2007, and 7.9% in 2008
received SSRIs. Concomitant use (BPsSSRIs) was observed in 0.4%women in 2004,
0.5% in 2005, 0.6% in 2006, 0.6% in 2007, and 0.6% in 2008. In 2006, 2007, and 2008,
concomitant use of BPsSSRIs was higher in the 65-85 age group compared to that
of 45-64 years. This pattern may be in large part due to increasing population of
older women in the United States. CONCLUSIONS: Concomitant use of BPs and
SSRIs in adult women 45 years is not uncommon and might be higher in older
postmenopausalwomen. The observed concomitant use presents drug safety chal-
lenges surrounding the bone health of postmenopausal women. Studies are
needed to investigate the potential interactive effects of SSRIs on BP therapy.
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OBJECTIVES: Tuberous sclerous complex (TSC) is a multi-system disorder that can
affect almost any organ system in the body. The objective of this study is to exam-
ine the prevalence and incidence rates of the common co-morbid conditions
among patients with TSC.METHODS:We used a large national health care claims
database for 39 million commercially insured US populations. Patients with a TSC
claim between 2000 and 2009, and continuous enrollment 12months before and 12
months after their first TSC diagnosis were included in this analysis (These selec-
tion criteria lead to the exclusion of those at age less than one). Approximately 40
TSC related clinical conditions were identified using ICD-9 codes or CPT codes. The
prevalence and incidence rates of these conditions are assessed and reported.
RESULTS: Patients (N1249) with TSC had mean age of 33.9 years at their 1st TSC
diagnosis, and 57.5% were females. The most prevalent comorbid conditions
within the first post TSC year were vision disorders (34.8%), benign neoplasm of
skin (28.1%), seizure (16.1%), convulsion (15.0%), dyschromia (12.2%), depression
(11.1%), cardiac dysrhythmia (9.1%), anxiety (8.6%), sleep disorder (7.8%) and he-
maturia (6.3%). The conditions with highest incidence rates (per 10,000 patient
years) in the same period were benign neoplasm of skin (1,361), vision disorders
(1,017), dyschrommia (480), seizure (464), and convulsion (456); subependymal gi-
ant cell astrocytoma (160) and Cardiac rhabdomyomas (80) were also observed.
CONCLUSIONS: TSC affects multi-systems and organs, and is associated with
many comorbid conditions. Vision disorders, benign skin cancer, seizure, convul-
sion, dyschromia, depression, cardiac dysrhythmia, anxiety, sleep disorders and
hematuria are the most prevalent ones in the real world. Managing TSC could be
challenging due to its multi-system involvement. Future effort should focus on
developing treatment that treat the underlying cause of the disease.
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OBJECTIVES: To estimate the budget impact (BI) of adding a new fixed-dose com-
bination (FDC) of 0.5mg dutasteride and 0.4mg tamsulosin daily to the Regie de
L’assuranceMaladie du Quebec (RAMQ) formulary for a three year period following
its listing for the treatment of symptomatic benign prostatic hyperplasia (BPH).
METHODS: The analysis compared RAMQdrug expenditures after the introduction
of FDC (New Drug Scenario) with an alternative scenario without FDC (Reference
Scenario). Treatments in the reference scenario include alpha blockers (tamsulo-
sin, doxazosin, terazosin, alfuzosin), 5-reductase inhibitors (finasteride, dutas-
teride) and their combinations. The treated population was assumed to be equal to
the population of men in Quebec aged 50 years with moderate to severe symp-
toms of BPH (estimated at 312,448). In the primary analysis, FDC was assumed to
gain 2.5%, 5.8% and 9.3% of BPH market share in the first 3 years after listing with
75% of share gains coming from patients switching from an alpha blocker plus
dutasteride, and 25% frompatients switching from tamsulosinmonotherapy. One-
way sensitivity analysis was performed to quantify the effect of uncertainty
around the market shares assumptions. RESULTS: In the primary analysis, adding
FDC to RAMQ is projected to result in a cost saving of $0.253M over three years.
Assuming only 60% of market share comes from patients currently taking dutas-
teride plus an alpha blocker, the total incremental BI is $5.879M over 3 years. If FDC
gains 90% of itsmarket shares from dutasteride plus an alpha blocker, the BI would
results in a cost saving of $6.386M over 3 years. CONCLUSIONS: Based on this
budget impact analysis, it may be cost-saving for the RAMQ to switch patients who
are treatedwith combination therapy of separate drugs of dutasteride and an alpha
blocker to a FDC of dutasteride and tamsulosin.
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OBJECTIVES: Epilepsy affects about 3 million people in the United States and ac-
counts for $17.6 billion/year in health care costs. Many antiepileptic drugs (AEDs)
are used to treat the disease, but some patients remain refractory. We compared
annual overall and epilepsy-relatedhealth care costs between refractory and stable
epileptic adults. METHODS: We identified adults (age18years) with epilepsy re-
quiring additional AED therapy (defined as refractory) and not requiring such ther-
apy (stable) from the MarketScan claims database in 2007-2009. An index date was
selected during calendar year 2008: the date on which an additional AED was
started for refractory patients; and convenience date for stable patientswhose AED
use was unchanged in the prior year. All pharmacy and medical claims in the
post-index year were used to estimate overall costs. Claims with epilepsy in any
diagnosis fieldwere used to estimate epilepsy-related costs. Analysis of covariance
was used to compare outcomes after adjusting for baseline differences between
groups.RESULTS:We identified 1536 refractory and 8571 stable patients (age range:
18-64years; 50.7% vs. 47.6% female; mean Charlson comorbidity index: 0.7 vs. 0.5).
Comparing refractory vs. stable patients the total health care costs were $23,238
(SD:$42,894) versus $13,839 (SD:$31,355) per patient-year (PPY) and epilepsy-related
costs were $12,399 (SD: $25,773) versus $5,511 (SD:$11,730) PPY (p0.001). Of epi-
lepsy-related costs, $7,257 (SD:$25,202) versus $2,751 (SD:$11,029) PPY were medi-
cal and $5,142 (SD:$4,110) versus $2,760 (SD:$3,361) PPY for AEDs (p0.001). After
adjusting for age, gender, region, usual care physician specialty, comorbidities and
risk factors, overall costs were significantly greater in the refractory compared to
stable patients: $7187 (p0.001). CONCLUSIONS: Although both refractory and sta-
ble epilepsy patients have a high economic burden, the costs incurred by patients
with refractory disease are significantly greater. Epilepsy-related costs comprised
under 50% of total costs, suggesting a substantial burden of comorbid conditions
and/or under-identification of epilepsy-related utilization.
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